GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vigil Neuroscience Inc (NAS:VIGL) » Definitions » Financial Strength

VIGL (Vigil Neuroscience) Financial Strength : 7 (As of Mar. 2025)


View and export this data going back to 2022. Start your Free Trial

What is Vigil Neuroscience Financial Strength?

Vigil Neuroscience has the Financial Strength Rank of 7.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.

A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

GuruFocus does not calculate Vigil Neuroscience's interest coverage with the available data. As of today, Vigil Neuroscience's Altman Z-Score is 0.00.


Competitive Comparison of Vigil Neuroscience's Financial Strength

For the Biotechnology subindustry, Vigil Neuroscience's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vigil Neuroscience's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vigil Neuroscience's Financial Strength distribution charts can be found below:

* The bar in red indicates where Vigil Neuroscience's Financial Strength falls into.


;
;

Vigil Neuroscience Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Vigil Neuroscience's Interest Expense for the months ended in Mar. 2025 was $0.00 Mil. Its Operating Income for the months ended in Mar. 2025 was $-23.47 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $11.62 Mil.

Vigil Neuroscience's Interest Coverage for the quarter that ended in Mar. 2025 is

GuruFocus does not calculate Vigil Neuroscience's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Vigil Neuroscience Inc has enough cash to cover all of its debt. Its financial situation is stable.

2. Debt to revenue ratio. The lower, the better.

Vigil Neuroscience's Debt to Revenue Ratio for the quarter that ended in Mar. 2025 is

Debt to Revenue Ratio=Total Debt (Q: Mar. 2025 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.07 + 11.623) / 0
=N/A

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Vigil Neuroscience has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vigil Neuroscience  (NAS:VIGL) Financial Strength Explanation

The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Vigil Neuroscience has the Financial Strength Rank of 7.


Vigil Neuroscience Financial Strength Related Terms

Thank you for viewing the detailed overview of Vigil Neuroscience's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Vigil Neuroscience Business Description

Traded in Other Exchanges
N/A
Address
100 Forge Road, Suite 700, Watertown, MA, USA, 02472
Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.
Executives
Ivana Magovcevic-liebisch director, officer: President and CEO 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Budd Haeberlein Samantha L. director VIGIL NEUROSCIENCE, INC., 100 FORGE ROAD, SUITE 700, WATERTOWN MA 02472
Christopher Silber officer: Chief Medical Officer C/O VIGIL NEUROSCIENCE, INC., 100 FORGE ROAD, SUITE 700, WATERTOWN MA 02472
Gray David L. F. officer: Chief Science Officer VIGIL NEUROSCIENCE, INC., 100 FORGE ROAD, SUITE 700, WATERTOWN MA 02472
Spyridon Papapetropoulos officer: Chief Medical Officer C/O ADAMAS PHARMACEUTICALS, INC., 1900 POWELL ST., SUITE 1000, EMERYVILLE CA 94608
Suzanne Louise Bruhn director C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
Clay Thorp director C/O HATTERAS VENTURE PARTNERS III, LP, 280 S. MANGUM ST., SUITE 350, DURHAM NC 27701
Evan Thackaberry officer: SVP, Head of Early Development VIGIL NEUROSCIENCE, INC., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Jennifer Lynn Ziolkowski officer: Chief Financial Officer C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Christopher Verni officer: General Counsel VIGIL NEUROSCIENCE, INC., 1 BROADWAY, 7TH FLOOR, SUITE 07-300, CAMBRIDGE MA 02142
Mary Thistle director C/O VIACELL, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
Atlas Venture Fund Xii, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Bruce Booth director 890 WINTER STREET, SUITE 320, WALTHAM MA 02451
Stefan Vitorovic director C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Northpond Ventures Gp, Llc 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814